Immunotherapy-based combinations have rapidly become the dominant first-line treatment for advanced hepatocellular carcinoma ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation. Their study, published in Nature Communications, reveals that the enzyme ...

A new study suggests that how neurons process energy may determine whether they resist damage or begin to break down.

Independent Evaluation Provides Ingredient Research Context, Consumer Considerations, and Realistic Expectation Framework for ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the Phase IV ...

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding response rates below 20% ...

Life’s most indispensable molecules are not the serene, unchanging fixtures they might appear to be. Even the proteins that ...

As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...